International Journal of Clinical Research

Objective To explore the value of using tumor markers and stool combined testing in the diagnosis and treatment of colorectal cancer. Methods The subjects of this study were 50 patients with colorectal cancer, selected from January 2023 to January 2024. Set the above patients as the experimental group, and select 50 healthy individuals who were admitted for health check ups during the same period as the reference group. Perform a combined test of tumor markers and stool for both groups mentioned above, observe and compare the test results of the two groups, and analyze the accuracy, specificity, and sensitivity of the combined test of tumor markers and stool. Results Compared with the reference group, the experimental group had a higher detection rate of bloody stool, mucous stool, and dysentery like purulent stool (P<0.05). The levels of CEA and CA199 in the serum of the experimental group were higher than those in the reference group (P<0.05). The accuracy, specificity, and sensitivity of fecal examination combined with tumor marker detection were higher than those of single test (P<0.05). Conclusion Fecal examination and tumor marker detection have certain reference value in the diagnosis of colorectal cancer. When fecal testing is combined with tumor marker detection, it can significantly improve the accuracy of diagnosis and exhibit high specificity and sensitivity.

Colorectal cancer; Tumor markers; Fecal examination; Application value